Browse the evidence

Semaglutide 2.4mg weekly induces significantly greater weight loss (mean 14.9%) compared to lifestyle interventions alone (mean 2.4%) in adults without diabetes.

Semaglutide 2.4mg taken once weekly, combined with a modest caloric deficit, can lead to an average 15% body weight loss in people without diabetes. This is significantly more effective than lifestyle changes alone and helps counteract the biological drive to regain weight.

GLP-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists (e.g., tirzepatide) induce significant weight loss and improve glycemic control primarily through delayed gastric emptying, reduced appetite, and central nervous system-mediated satiety pathways.

GLP-1 and dual agonists are highly effective for weight loss and blood sugar control, working by slowing digestion and signaling fullness to the brain. Start with the lowest dose to minimize stomach upset, and increase gradually as tolerated. Expect significant weight loss (up to 20% in some trials) and improved glucose levels, but be prepared for potential gastrointestinal side effects like nausea.

Anti-obesity medications (AOMs) including orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, and semaglutide are effective for long-term weight management in adults with BMI ≥ 25 kg/m² who have failed non-pharmacological treatments.

If you have obesity and lifestyle changes haven't worked, talk to your doctor about FDA-approved anti-obesity medications. Drugs like semaglutide (once-weekly injection or daily pill) and liraglutide (daily injection) can help you lose significant weight. Start with a low dose to minimize stomach upset, and work with your provider to find the right medication for your specific health needs.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates superior weight loss efficacy compared to other currently available AOMs in phase 3 trials.

Tirzepatide is a new once-weekly injection that targets two hormones (GIP and GLP-1) to help with weight loss. In clinical trials, it led to an average 22.5% body weight loss over 72 weeks. It starts at a low dose to minimize side effects and can be increased up to 15 mg weekly. Talk to your doctor about whether this advanced option is right for you.

Targeting specific neural circuits in the brainstem and hypothalamus using peptide-based pharmacotherapies (e.g., GLP-1 mimics) is an effective strategy for inducing weight loss and treating obesity.

Consult a healthcare provider about GLP-1 based treatments if lifestyle changes alone are insufficient. These medications work by targeting brain circuits to reduce appetite and increase satiety, offering a biologically targeted approach to weight loss.

Weekly administration of semaglutide (2.4 mg) and tirzepatide (15 mg) produces substantially greater weight loss (9.6% and 13.1% respectively) compared to pre-existing anti-obesity medications (approx. 5% weight reduction).

If you have type 2 diabetes and obesity, current guidelines suggest trying lifestyle changes first. If that fails, newer injectable medications like semaglutide (2.4 mg weekly) or tirzepatide (15 mg weekly) are significantly more effective at reducing body weight (around 10-13%) than older oral or injectable options (around 5%). These require a prescription and gradual dose titration to manage side effects.

Tirzepatide (15 mg) demonstrates superior weight loss efficacy compared to semaglutide (1 mg) in patients with type 2 diabetes, achieving 13.1% weight loss versus 9.7 kg (9.6%) for semaglutide 2.4 mg in direct comparison trials.

For patients with type 2 diabetes needing significant weight loss, tirzepatide (15 mg weekly) has shown higher weight loss percentages (13.1%) compared to semaglutide (1 mg weekly) in head-to-head trials. This requires a slow 20-week titration to manage side effects, which may impact adherence.

Lifestyle interventions (dietary changes and physical activity) are the foundational and preferred first-line treatment for obesity management, although they are difficult for many patients to maintain long-term.

Start with lifestyle changes: adjust your diet to reduce caloric intake and increase physical activity. This is the standard first step for treating obesity. If you find it difficult to maintain these changes, do not view this as a personal failure; the paper notes this is a common challenge. In such cases, consult a healthcare provider about adding pharmacological treatments or metabolic surgery as adjunctive or alternative options tailored to your specific needs.

Tirzepatide (5-15 mg subcutaneous once weekly) produces substantial body weight reduction (up to 21%) in adults with or without type 2 diabetes, with efficacy superior to GLP-1 mono-agonists like semaglutide.

Tirzepatide is a highly effective, once-weekly subcutaneous injection for weight loss, approved for adults with obesity or overweight with weight-related conditions. It works by mimicking hormones (GLP-1 and GIP) that regulate appetite and blood sugar. Clinical trials show significant weight loss (up to 21%) in people without diabetes and up to 15% in those with type 2 diabetes. Common side effects like nausea and diarrhea are usually temporary and can be managed by starting with a low dose and increasing gradually. It is superior to older GLP-1 medications in weight reduction.

Increasing potassium intake, particularly through salt substitution (25% KCl/75% NaCl) in populations with low potassium and high sodium intake, significantly reduces the risk of stroke and cardiovascular events.

If you live in a region where processed foods are common (high sodium) and fruit/vegetable intake is low, consider switching to a salt substitute containing 25% potassium chloride. This simple change has been shown in large trials to significantly reduce the risk of stroke and heart disease, especially if you have high blood pressure or a history of stroke. It is safe for most people, though those with advanced kidney disease should consult a doctor first.

Higher potassium intake is associated with lower blood pressure and reduced cardiovascular risk, independent of sodium intake levels, with benefits observed even when sodium reduction is modest.

Aim for a diet rich in potassium by eating more fruits, vegetables, legumes, and dairy. This helps lower blood pressure and reduces heart disease risk, even if you don't perfectly reduce your salt intake. If you use salt substitutes, choose ones with potassium chloride.

Semaglutide (2.4 mg/week) improves physical function and reduces body weight in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

If you have heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg weekly) can help you feel better, walk further, and lose weight. It is taken as a weekly injection, starting at a low dose to minimize side effects.

GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists (e.g., tirzepatide) significantly reduce body weight and improve glycemic control in patients with type 2 diabetes and obesity by stimulating insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite.

For individuals with obesity or type 2 diabetes, GLP-1 and GLP-1/GIP receptor agonists are highly effective treatments that promote significant weight loss and improve blood sugar control. These medications work by mimicking natural hormones to increase insulin, reduce glucagon, slow digestion, and decrease appetite. While they can cause gastrointestinal side effects like nausea, starting with a low dose and increasing it slowly helps manage these symptoms. They are particularly beneficial for those who have not achieved sufficient weight loss or cardiovascular risk reduction with lifestyle changes alone.

GLP-1 receptor agonists (GLP1RA) reduce body weight in humans primarily by reducing food intake, not by increasing energy expenditure.

GLP-1 medications like semaglutide and liraglutide work by reducing your appetite, not by speeding up your metabolism. This makes it easier to eat less, leading to significant weight loss (e.g., ~8.4 kg with liraglutide 3mg over 52 weeks). Focus on the reduction in food intake as the primary driver of weight loss.

GLP-1 receptor agonists reduce food intake and body weight in humans, with efficacy comparable to or rivaling bariatric surgery.

GLP-1 medications are effective for weight loss and may eventually rival bariatric surgery in efficacy. They offer a non-surgical option for treating obesity.

Obesity is the most significant risk factor for the development and progression of Type 2 Diabetes, with obesity accounting for 44% of diabetes cases globally.

Your weight is the biggest lever you have in preventing or managing Type 2 Diabetes. The data shows that carrying excess weight significantly increases your risk, so maintaining a healthy weight is the single most effective preventive measure available.

Muscle hypertrophy can be achieved with both high-load and low-load resistance training, provided that sets are performed to or near muscular failure, with no significant difference in whole muscle growth between loading zones.

You do not need to stick to a specific rep range (like 8-12) to build muscle. You can use heavy weights (low reps) or light weights (high reps) with equal effectiveness for muscle growth, as long as you push your sets close to failure. Choose the load that feels best for your joints and keeps you motivated.

Higher-load resistance training (≥80% 1RM) is the primary determinant for maximizing muscle strength gains, whereas multiple sets are the primary determinant for maximizing muscle hypertrophy.

If your main goal is to get stronger, prioritize lifting heavy weights (at least 80% of your one-rep max). If your main goal is to build muscle size, focus on doing multiple sets per exercise (e.g., 2-3 sets) rather than just one. You do not need to choose one goal over the other; high-load, multi-set training is the best of both worlds.

High cardiorespiratory fitness (CRF) attenuates or eliminates the mortality risk associated with high BMI, such that 'fit' obese individuals have lower mortality risk than 'unfit' normal-weight individuals.

If you have a high BMI, focus on improving your cardiorespiratory fitness through regular aerobic exercise. This can significantly reduce your mortality risk, potentially to levels lower than someone with a normal BMI who is physically unfit. Fitness is a vital sign.

GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists improve metabolic health in obesity and type 2 diabetes by lowering BMI, improving insulin sensitivity, and potentially activating thermogenic fat.

GLP-1 and GLP-1/GIP agonists are powerful tools for treating obesity and type 2 diabetes. They work by reducing appetite and improving how your body handles insulin and fat. These drugs have been shown to lead to significant weight loss (over 20% in some cases) and improve heart health. They are often used alongside lifestyle changes like diet and exercise.

Adherence to evidence-based dietary patterns (DASH, Mediterranean, or vegetarian) significantly reduces cardiovascular disease morbidity and mortality.

Adopt a dietary pattern rich in fruits, vegetables, whole grains, and legumes, while minimizing processed meats, sugary drinks, and saturated fats. The DASH, Mediterranean, and vegetarian diets are the most strongly supported for preventing heart disease. If cost is a barrier, use canned or frozen produce without added sugar and dried beans.

Adherence to a Mediterranean-style diet rich in unsaturated fatty acids (specifically extra-virgin olive oil or nuts) significantly reduces the risk of major cardiovascular events and type 2 diabetes compared to a low-fat control diet.

Replace refined carbohydrates and saturated fats with unsaturated fats, specifically by adding 4 tablespoons of extra-virgin olive oil or 30 grams of mixed nuts to your daily diet. You do not need to restrict calories or count fat grams; focus on incorporating these whole-food sources of healthy fats consistently.

Increased consumption of ultra-processed foods is a major contributor to the global pandemics of obesity, type 2 diabetes, and related non-communicable diseases.

Prioritize fresh or minimally processed foods (vegetables, fruits, grains, meats, dairy) and actively avoid ultra-processed foods (packaged snacks, sugary drinks, reconstituted meats, ready meals). Do not rely on 'reformulated' versions of these products as healthy alternatives; the processing level itself is the primary risk factor for obesity and metabolic disease.

Modest weight loss of 5-10% of baseline body weight significantly improves glycemic control (A1C reduction of 0.6-1.0%) and reduces the need for diabetes medications.

Aiming to lose just 5-10% of your current body weight can significantly lower your A1C by up to 1% and may allow you to reduce your diabetes medications. This is a realistic and highly effective initial target for managing diabetes.